Cone-Rod Dystrophy Overview
Learn About Cone-Rod Dystrophy
Cone-rod dystrophy is a group of related eye disorders that causes vision loss, which becomes more severe over time. These disorders affect the retina, which is the layer of light-sensitive tissue at the back of the eye. In people with cone-rod dystrophy, vision loss occurs as the light-sensing cells of the retina gradually deteriorate.
Mutations in more than 30 genes are known to cause cone-rod dystrophy. Approximately 20 of these genes are associated with the form of cone-rod dystrophy that is inherited in an autosomal recessive pattern. Mutations in the ABCA4 gene are the most common cause of autosomal recessive cone-rod dystrophy, accounting for 30 to 60 percent of cases. At least 10 genes have been associated with cone-rod dystrophy that is inherited in an autosomal dominant pattern. Mutations in the GUCY2D and CRX genes account for about half of these cases. Changes in at least two genes cause the X-linked form of the disorder, which is rare.
Cone-rod dystrophy is estimated to affect 1 in 30,000 to 40,000 individuals.
Cone-rod dystrophy is usually inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.
Christina Zeitz practices in Paris, France. Ms. Zeitz is rated as an Elite expert by MediFind in the treatment of Cone-Rod Dystrophy. Her top areas of expertise are X-Linked Congenital Stationary Night Blindness, Cone-Rod Dystrophy, Retinopathy Pigmentary Mental Retardation, Late-Onset Retinal Degeneration, and Vitrectomy.
Isabelle Audo practices in Paris, France. Ms. Audo is rated as an Elite expert by MediFind in the treatment of Cone-Rod Dystrophy. Her top areas of expertise are Cone-Rod Dystrophy, X-Linked Congenital Stationary Night Blindness, Retinopathy Pigmentary Mental Retardation, Retinitis Pigmentosa, and Vitrectomy.
Saddek Said-Mohand practices in Paris, France. Said-Mohand is rated as an Elite expert by MediFind in the treatment of Cone-Rod Dystrophy. Their top areas of expertise are Cone-Rod Dystrophy, Retinitis Pigmentosa, Retinopathy Pigmentary Mental Retardation, Late-Onset Retinal Degeneration, and Vitrectomy.
Summary: Study OpCT-001-101 is a Phase 1/2a first-in-human, multisite, 2-part interventional study to evaluate the safety, tolerability, and the effect on clinical outcomes of OpCT-001 in up to approximately 54 adults with primary photoreceptor (PR) disease. Phase 1 will focus on safety and features a dose-escalation design. Phase 2 is designed to gather additional safety data and assess the effect of OpCT...
Summary: This is a two-step, multicenter, Phase I/II study including an open-label dose-escalation phase (Step 1) and a three-arm, controlled, double-masked, randomized extension phase (Step 2), in subjects with advanced RCD due to a mutation in the RHO, PDE6A, or PDE6B gene.
Published Date: March 01, 2018
Published By: National Institutes of Health